Viking Therapeutics Business Summary

Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company that operates through a research-intensive business model, currently generating value through the development of its therapeutic pipeline rather than commercial product sales. The company focuses on small molecule therapies for metabolic and endocrine disorders, with primary business segments organized around its lead candidates: obesity and type 2 diabetes (VK2735), non-alcoholic steatohepatitis or MASH (VK2809), and rare diseases like X-linked adrenoleukodystrophy (VK0214). Viking competes directly with Eli Lilly, Novo Nordisk, and Madrigal Pharmaceuticals, positioning itself as a high-potential mid-cap disruptor. Its competitive edge lies in the dual-agonist profile of VK2735, which is being advanced in both subcutaneous and oral formulations to challenge the market dominance of established GLP-1 and GIP therapies. The company is led by Co-founder, President, and CEO Brian Lian, Ph.D., a former Amgen scientist and SunTrust Robinson Humphrey analyst with deep expertise in endocrine drug discovery. The executive team was significantly bolstered in January 2026 by the appointment of Chief Commercial Officer Neil Aubuchon, an industry veteran with over 20 years of experience at Eli Lilly and Amgen. Other key leaders include CFO Greg Zante, COO Marianne Mancini, and Chief Development Officer Geoffrey Barker, Ph.D., who oversee the company's transition toward late-stage clinical milestones. Viking’s strategic direction is guided by a board that includes Charles A. Rowland Jr. and is backed by significant institutional ownership, which remains stable at approximately 67% as of March 2026.